These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34010086)

  • 21. Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD).
    Kawecka K; Theodoulides M; Hasoglu Y; Jarmin S; Kymalainen H; Le-Heron A; Popplewell L; Malerba A; Dickson G; Athanasopoulos T
    Curr Gene Ther; 2015; 15(4):395-415. PubMed ID: 26159373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adeno-associated virus mediated gene therapy for retinal degenerative diseases.
    Stieger K; Cronin T; Bennett J; Rolling F
    Methods Mol Biol; 2011; 807():179-218. PubMed ID: 22034031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic antisense and ribozymes.
    Rossi JJ
    Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense oligonucleotides.
    Kashihara N; Maeshima Y; Makino H
    Exp Nephrol; 1998; 6(1):84-8. PubMed ID: 9523178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics.
    Scharner J; Aznarez I
    Mol Ther; 2021 Feb; 29(2):540-554. PubMed ID: 33359792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
    Garanto A; Collin RWJ
    Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adeno-associated virus-vectored gene therapy for retinal disease.
    Dinculescu A; Glushakova L; Min SH; Hauswirth WW
    Hum Gene Ther; 2005 Jun; 16(6):649-63. PubMed ID: 15960597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthetic Adeno-Associated Viral Vector Efficiently Targets Mouse and Nonhuman Primate Retina In Vivo.
    Carvalho LS; Xiao R; Wassmer SJ; Langsdorf A; Zinn E; Pacouret S; Shah S; Comander JI; Kim LA; Lim L; Vandenberghe LH
    Hum Gene Ther; 2018 Jul; 29(7):771-784. PubMed ID: 29325457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repression of transforming growth factor beta 1 protein by antisense oligonucleotide-induced increase of adrenal cell differentiated functions.
    Le Roy C; Leduque P; Dubois PM; Saez JM; Langlois D
    J Biol Chem; 1996 May; 271(18):11027-33. PubMed ID: 8631925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense Therapy for Infectious Diseases.
    Buthelezi LA; Pillay S; Ntuli NN; Gcanga L; Guler R
    Cells; 2023 Aug; 12(16):. PubMed ID: 37626929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene Therapy for Hemophilia and Duchenne Muscular Dystrophy in China.
    Liu X; Liu M; Wu L; Liang D
    Hum Gene Ther; 2018 Feb; 29(2):146-150. PubMed ID: 29366352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
    Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
    J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives.
    Rolling F
    Gene Ther; 2004 Oct; 11 Suppl 1():S26-32. PubMed ID: 15454954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in therapeutic RNA-targeting.
    van Ommen GJ; Aartsma-Rus A
    N Biotechnol; 2013 Mar; 30(3):299-301. PubMed ID: 23369867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Locked nucleic acid antisense inhibitor targeting apolipoprotein C-III efficiently and preferentially removes triglyceride from large very low-density lipoprotein particles in murine plasma.
    Yamamoto T; Obika S; Nakatani M; Yasuhara H; Wada F; Shibata E; Shibata MA; Harada-Shiba M
    Eur J Pharmacol; 2014 Jan; 723():353-9. PubMed ID: 24269597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina.
    Grant CA; Ponnazhagan S; Wang XS; Srivastava A; Li T
    Curr Eye Res; 1997 Sep; 16(9):949-56. PubMed ID: 9288458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
    Ly CV; Miller TM
    Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.